Kim, 235 patient metformin prophylaxis study: 64% lower mortality [p=0.1] and 52% lower progression [p=0.13] https://c19p.org/kim3
copied to clipboard
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
et al., Diabetes & Metabolism Journal, doi:10.4093/dmj.2020.0146
Retrospective 235 hospitalized diabetes patients in South Korea, showing lower mortality and lower progression to severe disease with metformin.
|
risk of death, 64.0% lower, OR 0.36, p = 0.10, treatment 113, control 122, adjusted per study, multivariable, RR approximated with OR.
|
|
risk of progression, 52.0% lower, OR 0.48, p = 0.13, treatment 113, control 122, adjusted per study, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Kim et al., 8/12/2020, retrospective, South Korea, Asia, peer-reviewed, 32 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.